ClinicalTrials.gg
CompletedNCT01084265Updated Dec 27, 2013Results posted

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

A Phase 3 interventional study of Recombinant human luteinizing hormone (r-hLH) and Recombinant human follicle-stimulating hormone (r-hFSH) in Hypogonadism, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Sex
Female
01

Study summary

This was a prospective, open, non-comparative study to evaluate the safety and efficacy of recombinant human luteinizing hormone (rhLH, Luveris) administered subcutaneously (s.c.) in follicular development during ovulation induction in 31 Chinese female subjects with hypogonadotropic hypogonadism.

Read the detailed description

The objective of this prospective, open, non-comparative study was to assess the safety and efficacy of rhLH (Luveris) administered subcutaneously in follicular development during ovulation induction in Chinese female subjects with hypogonadotropic hypogonadism. The study was organized on an outpatient basis involving a single cycle of treatment. Prior to entry into the study, the diagnosis of hypogonadotropic hypogonadism was confirmed by history, by the presence or absence of specific clinical features and by measuring serum gonadotropin levels. Once a subject has signed the informed consent form and after satisfying all eligibility criteria, the subject received a combination of daily injection of recombinant human follicle-stimulating hormone (rhFSH) 150 international units (IU) plus rhLH 75 IU. After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU human chorionic gonadotropin (hCG). Luteal phase function was assessed by serum progesterone level determination.

02

Conditions studied

  • Hypogonadism

Browse trials for

Keywords

  • Hypogonadism
  • Recombinant human follicle stimulating hormone (r-hFSH)
  • Recombinant leutinizing hormone (r-hLH)
03

In context

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

This study's enrollment of 31 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.

Browse Hypogonadism studies →

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be premenopausal, between 18 and 39 years of age
  • Have a clinical history of hypogonadotropic hypogonadism, and laboratory test result comply with diagnosis of hypogonadotropic hypogonadism during screening procedure
  • Have discontinued gonadotropins, gonadotropin-releasing hormone (GnRH) (gonadotropin naïve), or estrogen progesterone replacement therapy at least one month before the screening procedure
  • Have a negative progestin challenge test performed during screening
  • Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 months before initiation of treatment:
  • Follicular stimulating hormone (FSH): \< 5 international units/liter (IU/L)
  • Luteinizing hormone (LH): \< 1.2 IU/L
  • Oestradiol (E2): \< 60 picogram/milliliter (pg/mL) (\<220 picomolar/liter [pmol/L])
  • Prolactin (PRL): \< 44.3 nanogram/milliliter (ng/mL) (\< 1040 milli-international units/liter [mIU/L])
  • Thyrotrophin-stimulating hormone (TSH): \< 6.5 micro-international units (uIU/mL)
  • Free Thyroxine (T4): 0.8-1.8 nanogram/deciliter (ng/dL) (11-24 pmol/L)
  • Triiodothyronine (T3): \< 1.0 ng/mL (\< 3.5 nanomolar/liter [nmol/L])
  • Have an endovaginal pelvic ultrasound scan showing (i) no ovarian tumor and cyst \< 2 centimeters (cm); (ii) no uterine abnormality, and (iii) \< 13 mm small follicles (mean diameter \< 10 mm) on the largest section through each ovary
  • Have a normal cervical pap smear within 6 months of the initial visit
  • Have a (BMI) between 18.4 and 31.4 kilogram/meter square (kg/m\^2)
  • Be willing and able to comply with the protocol for the duration of the study
  • Have given written prior to any study related procedure

Exclusion criteria

Exclusion Criteria:

  • Ongoing pregnancy
  • Any chronic systemic disease
  • Hypersensitive to study drug and control drug
  • History of severe ovarian hyperstimulation syndrome
  • Abnormal gynecological bleeding of undetermined origin
  • Previous or current hormone dependent tumor
  • Known active substance abuse or eating disorder
  • Known central nervous system (CNS) lesions: In cases where hypogonadotropic hypogonadism (HH) is secondary to a CNS lesion or its treatment, the subject will not be eligible without consulting Serono's Medical Director
  • Exercise program exceeding 10 hours per week
  • Currently undergoing treatment with psychotropic medication or with any other medication known to interfere with normal reproductive function (for example, neuroleptics, dopamine antagonists)
  • There is any abnormality, decided by investigators, which might produce effect on the absorption, distribution and excretion of drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Met Both Index 1 and Index 2

    The three indices were defined as; Index 1: diameter of at least one follicle is greater than 17 mm; Index 2: serum oestradiol (E2) level in blood serum above 109 picogram/ milliliter (pg/mL) on human chorionic gonadotropin (hCG) injection day; Index 3: participant refuses to take hCG injection for the concern of ovarian hyperstimulation syndrome (OHSS) or participant is pregnant. A subset of these participants met Index 3.

    Time frame: Day 14

  2. Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter

    Time frame: Day 14

  3. Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection

    Time frame: Day 14

  4. Number of Participants Who Refused to Take hCG Injection

    Participant refused to take hCG injection for the concern of OHSS or the participant was pregnant.

    Time frame: Day 14

Secondary outcomes

  1. Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle

    Time frame: Day 14

  2. Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle

    Time frame: Day 14

  3. Average Change of E2 Level in Participants Per Day up to Day 14

    The average change was calculated by assessing the E2 levels on 4 timepoints until day 14 (day 1, day 5, day 10, day 14 \[hCG administration day\]).

    Time frame: up to Day 14

  4. Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies

    Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy. Clinical pregnancy was defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

    Time frame: Day 14

  5. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

    Time frame: Day 14

07

Results

Posted May 22, 2012

Participant flow

Participant flow — Overall Study
MilestoneRecombinant Human Luteinizing Hormone (Luveris)
Started31
Completed31
Not completed0

Outcome measures

PrimaryNumber of Participants Who Met Both Index 1 and Index 2

The three indices were defined as; Index 1: diameter of at least one follicle is greater than 17 mm; Index 2: serum oestradiol (E2) level in blood serum above 109 picogram/ milliliter (pg/mL) on human chorionic gonadotropin (hCG) injection day; Index 3: participant refuses to take hCG injection for the concern of ovarian hyperstimulation syndrome (OHSS) or participant is pregnant. A subset of these participants met Index 3.

Time frame:
Day 14
Reported as:
Number · participants
Number of Participants Who Met Both Index 1 and Index 2
participantsRecombinant Human Luteinizing Hormone (Luveris)
Number of Participants Who Met Both Index 1 and Index 223
PrimaryNumber of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter
Time frame:
Day 14
Reported as:
Number · participants
Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter
participantsRecombinant Human Luteinizing Hormone (Luveris)
Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter23
PrimaryNumber of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection
Time frame:
Day 14
Reported as:
Number · participants
Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection
participantsRecombinant Human Luteinizing Hormone (Luveris)
Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection23
PrimaryNumber of Participants Who Refused to Take hCG Injection

Participant refused to take hCG injection for the concern of OHSS or the participant was pregnant.

Time frame:
Day 14
Reported as:
Number · participants
Number of Participants Who Refused to Take hCG Injection
participantsRecombinant Human Luteinizing Hormone (Luveris)
Refused due to concern of OHSS0
Refused due to pregnancy10
SecondaryMean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle
Time frame:
Day 14
Reported as:
Mean · follicles
Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle
folliclesRecombinant Human Luteinizing Hormone (Luveris)
Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle3.57 ± 4.07
SecondaryMean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle
Time frame:
Day 14
Reported as:
Mean · follicles
Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle
folliclesRecombinant Human Luteinizing Hormone (Luveris)
Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle2.13 ± 2.00
SecondaryAverage Change of E2 Level in Participants Per Day up to Day 14

The average change was calculated by assessing the E2 levels on 4 timepoints until day 14 (day 1, day 5, day 10, day 14 \[hCG administration day\]).

Time frame:
up to Day 14
Reported as:
Mean · pg/mL per day
Average Change of E2 Level in Participants Per Day up to Day 14
pg/mL per dayRecombinant Human Luteinizing Hormone (Luveris)
Average Change of E2 Level in Participants Per Day up to Day 1471.03 ± 64.53
SecondaryNumber of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies

Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy. Clinical pregnancy was defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

Time frame:
Day 14
Reported as:
Number · participants
Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies
participantsRecombinant Human Luteinizing Hormone (Luveris)
Biochemical Pregnancies1
Clinical Pregnancies9
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

Time frame:
Day 14
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsRecombinant Human Luteinizing Hormone (Luveris)
Adverse Events0
Serious Adverse Events0

Adverse events

Collected over Day 14. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recombinant Human Luteinizing Hormone (Luveris)—0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Recombinant Human Luteinizing Hormone (Luveris)
Mean30.1 ± 4.09
Sex: Female, Male
Sex: Female, Male(Participants)Recombinant Human Luteinizing Hormone (Luveris)
Female30
Male0
08

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, 100730, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 10, 2010
Start
Feb 2004
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Results first posted
May 22, 2012
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01084265
Collaborators
Merck Pte. Ltd., Singapore
Responsible party
Sponsor
First posted
Mar 10, 2010
Start date
Feb 2004
Primary completion
Dec 2005
Completion
Dec 2005
Results posted
May 22, 2012
Last update
Dec 27, 2013

Study contacts

Xin Li
study director · Merck Pte. Ltd., Singapore
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutropin alfa

Start the discussion